Efficacy, safety, and cost-effectiveness of pegylated PEG-rhg-CSF in pediatric patients receiving high-intensity chemotherapy: results from a phase II study

• Main Authors: Junting Huang (Author), Jia Zhu (Author), Lian Jiang (Author), Jiaqian Xu (Author), Xiheng Lin (Author), Jian Chang (Author), Xiaohong Zhang (Author), Suying Lu (Author), Feifei Sun (Author), Juan Wang (Author), Yi Que (Author), Zhonglv Ye (Author), Lihua Yang (Author), Xiuli Yuan (Author), Weisong Cai (Author), Chuan Tian (Author), Yanpeng Wu (Author), Xiangling He (Author), Yan-Lai Tang (Author), Yizhuo Zhang (Author)
• Format: Book
• Published: Frontiers Media S.A., 2024-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

BackgroundHigh-intensity chemotherapy can cause life-threatening complications in pediatric patients. Therefore, this study investigated safety and efficacy of long-acting pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF; Jinyouli®) in children undergoing high-intensity...